Zika Virus Not your daddy's arbovirus (hopefully)



Michael Libman MD J.D. MacLean Centre for Tropical Diseases McGill University

NO CONFLICT OF INTEREST TO DECLARE (EXCEPT ON CATMAT GUIDELINES COMMITTEE)

U.S. officials: The more we know about Zika, the scarier it is

What Every Woman Needs to Know About Zika

REAKING NEWS

Zika 'spreading explosively'

'Level of alarm is extremely high' about virus, WHO leader says Photos | 5 things you need to know | The children of Zika | Opinion: How to stop it | Map: Tracking the virus

Alexandra Sifferlin @acsillerlin April 22, 2010

Full coverage of the outbreak

HEALTH ZIKA

The New Hork Times Zika Is Coming in

By PETER J. HOTEZ APRIL 8, 2016

HUFFPOST HEALTHY LIVING An Illustrated Guide To The Zika Outbreak

Zika virus

The virus is suspected of causing birth defects and a rare autoimmune disorder.

CANADA

TRENDING RIP Prince | Ghosts of Vietnam | NDP | Attawapiskat | Bosma | Jays | Trump

Seven B.C. residents, including two pregnant women, test positive for Zika virus that causes birth defects

The Washington Post

PAMELA FAYERMAN, POSTMEDIA NEWS | April 19, 2016 8:47 AM ET More from Postmedia News

Thanks: Ling Yuan Kong

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. Vol. 46. No. 5. September, 1952.

COMMUNICATIONS

ZIKA VIRUS

(I). ISOLATIONS AND SEROLOGICAL SPECIFICITY

BY

G. W. A. DICK,

The National Institute for Medical Research, London

S. F. KITCHEN,

Formerly staff member of the Division of Medicine and Public Health, The Rockefeller Foundation, New York, U.S.A.

AND

A. J. HADDOW,

Formerly staff member of International Health Division, The Rockefeller Foundation, New York, U.S.A.

(From the Virus Research Institute, Entebbe, Uganda.)

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, Vol. 50. No. 5. September, 1956.

> Virus inoculated via mouse brain suspension to a 34 year old European male: fever, headache 3.5 days after inoculation

ZIKA VIRUS INFECTION EXPERIMENTALLY INDUCED IN A HUMAN

VOLUNTEER

BY

W. G. C. BEARCROFT*


West African Council for Medical Research Laboratories, Lagos, Nigeria.



Where is Zika?

Transmission modes – what do we know
 Manifestations, Diagnosis – quick recap
 Risk assessment
 Recommendations - Guidelines

Zika Virus



Single stranded RNA virus of Flavivirus genus Closely related to dengue, West Nile, yellow fever, and Japanese encephalitis viruses Arbovirus: arthropod-borne virus Primary vector - Ae. aegypti but several other Aedes spp. and Culex spp. capable of transmission (in laboratory)

-Strain dependent

Two Distinct Zika Lineages – Only One Serotype

- African
- Asian
 - All strains have identical surface antigens
 - Antibodies elicited after infection with Asian lineage potently inhibit both lineages *in vitro*
 - Sequence homology 90% (primer problems)
 - Dowd K et al. Cell Reports 2016
 - Enfissi A et al Lancet 2016

Epidemiology

Discovered in Zika Forest, Uganda 1947




Epidemiology

First human case diagnosed 1962-3 in Uganda

Serosurveys – neutralizing antibodies in East and West Africa, India, and SE Asia

Late 1940s to late 1990s

- Outbreaks in Yap, Micronesia in 2007
 - First cases outside Asia/Africa, first outbreak
 - French Polynesia 2013, Easter Island 2014
- Brazil early 2015 then spread in the Americas
 - Chen & Hamer. Ann Int Med 2016
 - Musso & Gubler. Clin Microbiol Rev July 2016






Countries and territories of the Americas with confirmed autochthonous cases of Zika virus (vector-borne transmission), 2015-2017

Data as of 27 April 2017 2:00 PM EST



source: Cases reported by the IHR National Focal Points to the WHO IHR Regional Contact Point for the Americas and through the Ministry of Health websites, 2017. Note: Further information regarding subnational geographic distribution of Zika virus cases is available on the Ministry of Health websites. For more details on country totals please visit Cumulative Cases table at

Map Production: PAHO Health Emergencies Department (PHE) / Health Emergency Information & Risk Assessment (HIM); 2017 Updated as of 27 April 2017. Washington, D.C. Suggested citation: Pan American Health Organization / World Health Organization. Countries and territories of the Americas with confirmed autochthonous cases of Zika virus (vector-borne transmission), 2015-2017. Washington, D.C.



Why has Zika emerged now?

- Naïve populations in South Pacific amplified virus and facilitated spread via global mobility
- Abundance of competent vectors in the Americas
- Antibody-dependent enhancement in a heavily dengue-exposed population
- Mutational change ('Asia strain') enhanced viral infectivity of *Aedes* vectors
- Mutational change higher human viremia and improved transmission efficiency

Probable Sentinel Cases

2012: Indonesia (diagnosed in Australia) Kwong JC et al. AJTMH 2013 2014: the Philippines (dx in Germany) – First case since 2012 for this country 2013: Thailand (dx in Canada) - Serological data in Thailand from the 1950s Fonseca C et al. AJTMH 2014 2015: Vietnam (dx in Israel) – Serological data in Vietnam from the 1950s Pond WL. Trans R Soc Trop Med Hyg 1963

Sentinel Cases

2010: Cameroon (diagnosed) retrospectively in Belgium) - Only reported case in Cameroon since 2010 2015: Kirabati (dx in New Zealand) – First known report April 2016: East Timor (dx in Germany) - First known report although only probable




Figure 2. Map of Asian countries in which Zika virus circulation has been reported up to September 1, 2016.

Transmission – Other Modes

Proven:

Sexual

Male to female; male to male; female to male

Blood products

– Documented in Brazil and French Polynesia

Theoretically possible, with serious implications:

Breast milk (Colt PLOS NTD april 2017)

- 3 cases, 1 culture pos (VL 850k/ml) day 4 postpartum


No clear transmission to child by milk

Saliva or tears

Transplantation

Transmission – Transfusion

- Martinique January to June 2016
 - Screened 4129 blood donations
 - 1.84% positive by nucleic acid testing
- Contacted donors to determine whether they were or became symptomatic
 - Mean log₁₀ RNA higher if symptomatic (P = .0013)
 - Symt:asympt 1:1Gallian P et al. Blood 2017




Sexual Transmission

Preliminary semen carriage studies:

- Up to 188 days by PCR. Mean 34, CI 28-41
- Unpublished intermittent shedding upto 1 yr (ECDC)
- Replication competent Zika in semen for 69 days
 But RNA virus: likely real
- High viral load in semen (and urine)
- Rarely hematospermia or microhematospermia
- Viral shedding in vaginal secretions to 14 days and in cervical mucus to day 11 post-symptom onset
- Time from sexual contact to symptom onset 8-21 days
 - Hamer DH et al. Curr Infect Dis Rep 2017
 - Russell K et al. Clin Infect Dis 2016
 - Paz-Bailey NEJM 2017

Clinical symptoms and signs in 93 patients with Zika virus disease acquired in the Americas



Hamer DH et al. GeoSentinel case series Ann Int Med 2016

rash

esy of

Maculopapular rash after travel to Haiti

/, land,

Maculopapular rash after travel to Haiti

Photo courtesy of Marc Shaw, Auckland, NZ

Zika rash

Less Common Signs

- Joint swelling
- GI: diarrhea, nausea, vomiting
- Paraesthesias
- Retro-orbital pain
- Pharyngitis
- Dysgeusia
- Subcutaneous hematomas
- Epididymitis

Substantial Clinical Overlap Among Common Arboviruses

Feature	Zika	Dengue	Chikungunya
Fever	++	+++	+++
Rash	+++	+	++
Arthralgia/ arthritis	++	+	+++
Conjunctivitis	++	-	-
Myalgia	+	++	+
Headache	+	++	++
Hemorrhage	Rare	+/-	-
Shock	-	+	-

Co-infection Data for 346 Nicaragua Children Waggoner JJ et al. CID 2016

ZCD Assay Result	Number, n (% of all Samples)		
Positive	263 (76.0)		
Monoinfections	192 (55.5)		
ZIKV	47 (13.6)		
CHIKV	91 (26.3)		
DENV ^a	54 (15.6)		
Coinfections	71 (20.5)		
ZIKV-CHIKV	16 (4.6)		
ZIKV-DENV ^a	6 (1.7)		
CHIKV-DENV ^a	43 (12.4)		
ZIKV-CHIKV-DENV ^a	6 (1.7)		
Negative	83 (24.0)		

Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; ZCD, multiplex real-time reverse-transcription polymerase chain reaction for the detection and differentiation of ZIKV, CHIKV, and DENV; ZIKV, Zika virus.

* Serotypes of 109 DENV-positive samples: DENV-2, 107; DENV-1, 1; DENV-4, 1.

Zika Neurological Complications

Congenital Zika syndrome - Fetal brain disruption sequence In vitro: Asian strain only ZIKV^{AF} –monkey adapted - Cugola, Nature 2016 Guillain-Barré syndrome (GBS) Meningoencephalitis Acute myelitis Hearing loss Posterior uveitis

So – what's our advice? Risk assessment

Risk of CZS if infected (USA registry)
 – Approx 5% (51/1297 pregnancies)

- 10% if lab confirmed (24/250),
 - 15% 1st trimester (9/60)
- 30x higher than baseline
- 1/5 risk of 1st trimester rubella

Risk of GBS

- About 1/4000 cases (cf Campylobacter)
- Maybe faster, milder
- Acute motor axon type

MMWR April 7 2017, Song BH, J neuroimmunol 2017

When is the risk?

1st trimester – consistently shows highest risk

- Peri-conception: theoretically low risk, but not supported by epi data
- Placental persistence

All pregnancy

- Interrupted brain development at any stage
- May seem normal at delivery
- Should be imaged
- After delivery??
 - Low inoculum, more intact BBB

Risk assessment Where are travelers getting Zika?

Region of Travel	Canada (n=482)ª	Country visits from Canada over two years ^b	United States (n=2,382) ^c	England (n=295) ^d
Carribbean	65% (313)	7,328,800	65% (1,545)	73% (215)
South America and Central America	19% (92)	2,921,800	27% (658)	23% (68)
N America	9% ^e (43)	4,330,800 ^g	5% (111)	2% (6)
Cumulative % from the Americas	99.6%		99%	98.6%
<u>Asia</u>	0.4% ^f (2)	5,395,800	<1% (11)	1.7% ⁱ (4)
Oceania	0% (0)	<u>390,200^h</u>		
<u>Sub-Saharan</u> <u>Africa</u>	0% (0)	1,237,600	0% (0)	0% (0)

Many numbers are estimates extrapolated from multiple sources, not official

WHO Classifications of Zika Transmission

Category 1:

- Countries with a reported outbreak from 2015 onwards
- e.g. Angola, Brazil, Maldives, USA
- Category 2:
 - Countries with evidence of transmission before 2015 and ongoing transmission
 - e.g. Haiti, Viet Nam

WHO/CDC Classifications of Zika Transmission

Category 3:

- Countries with evidence of local mosquito-borne Zika infections in or before 2015, but without documentation of cases since, or outbreak terminated (interrupted transmission) (potential future transmission?)
 e.g. Easter Island, French Polynesia

Category 4:

- Established competent vector, no known transmission
- e.g. most of Africa, Uruguay, various islands

CDC Recommendations for pregnant women

- Category 1 (plus Haiti, not USA): Travel health notice – do not travel
- Category 2, some cat 4
 - (38 countries, incl most of Africa, Asia)
 - Should not travel
 - Includes most of the tropical world
- Sexual transmission precautions for all
- Based on uncertainty in risk
- Implications for insurance, personal ??

How can we estimate the risk?

Asia:

- 1 zika case / 2.5 million trips
- So really 1/250,000 (1/5 symptomatic-say 1/10)
- Risk of CZS 1/2,500,000 (6% say 10%)
- Maybe 1/250,000 (10-fold under estimate)
- S/C America, Caribbean = 100x higher
 Compare:
 - Risk of maternal death 1/5000 live births
 - Risk of death by MVA 1/7000/year (x40 in Africa)
 - Baseline risk of major malformation 1-3/100
 - Baseline risk of "Zika-like" malformation 3/1000

Other types of pregnancy risk

Risk of congenital rubella syndrome: – 65-85% in 1st 2 months of gestation Major screening and vaccination programs Congenital CMV syndrome: - 50% of primary infections, 1/400 pregnancies – No program CATMAT: >1/10,000 = travel advisory during pregnancy – So Category 1 + Haiti

CATMAT

Pregnancy

- Cat 1: avoid travel
- Cat 2: moderate risk, 3-4 low risk
- Cat 2-4: consider postponing, caution for malaria, discuss with couple, values/preference/risk tolerance
- Sexual contact: Cat 1 = usual avoidance rec's
 - Cat 2-4: avoidance measures not routinely recommended, but discuss

ECDC

Make modifications of WHO cat's

- Subdivide cat 1 countries into regions when possible
- Cat 2+ = areas of cat 2 with "new documented intense transmission" (>10 cases/3 mo, or cases in >1 region)
 Eg Vietnam, Philippines
- 4a: no transmission, but border cat 2
- 1, 2+ = high, 2=mod, 3, 4a=low, 4=very low
 - No specific recommendations

Big questions

- Why is Brazil CZS rate >> USA? (29% vs 6%)
 - USA registry based
 - Maybe more severe entered registry
 - Maybe cases occurring outside of registry
 - Outcomes detection systems/methods
 - few infants PCR+, some IgM-, imaging erratic, multiple outcomes
 - Demographic/genetic differences (age)
 - Co-morbidities, exposure to cofactors (dengue?)
 - Not viral strain
 - USA rates higher than French Polynesia (1%)

Big questions

Is epidemic peaking?

In South America, still waves of outbreaks, but less than 2016
 Argentina this austral summer

- Central America: moving north through the summer
 USA? Hawaii? Australia?
- Caribbean: Very slow in Martinique, Guadeloupe, St Martin, French Guiana

French Polynesia: outbreak terminated at 50% seroprevalence


New Caledonia 12%

– Aubry M EID 2017, Musso CMR 2016

What about late term or post partum exposure

Subtle imaging changes?
 Subtle cognitive changes?
 – Cf toxoplasma

Where is the epidemic going?



De Oliveira WK NEJM 2017